Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis
- DOI
- 10.1016/j.critrevonc.2026.105697
- Published
- 2026-11
- Container
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.critrevonc.2026.105697,
title = {Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis},
author = {Wenwei Yang and Qi Cao and Biyang Cao and Jingyu Lu and Letian Zhang and Demei Feng and Lin Yang},
year = {2026},
journal = {Critical Reviews in Oncology/Hematology},
doi = {10.1016/j.critrevonc.2026.105697},
url = {https://doi.org/10.1016/j.critrevonc.2026.105697}
}RIS
TY - JOUR TI - Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis AU - Wenwei Yang AU - Qi Cao AU - Biyang Cao AU - Jingyu Lu AU - Letian Zhang AU - Demei Feng AU - Lin Yang PY - 2026 JO - Critical Reviews in Oncology/Hematology DO - 10.1016/j.critrevonc.2026.105697 UR - https://doi.org/10.1016/j.critrevonc.2026.105697 ER -
APA
Yang, W., Cao, Q., Cao, B., Lu, J., Zhang, L., Feng, D., & Yang, L. (2026). Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2026.105697
Source records
- crossref · retrieved 2026-11-10T12:24:55.269Z